On January 5, 2022 Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, reported its participation in two investor conferences as follows (Press release, Aeglea BioTherapeutics, JAN 5, 2022, View Source [SID1234598255]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference: 40th Annual J.P. Morgan Health Care Conference, January 10-13, 2022
Live Presentation Date/Time: Wednesday, January 12 at 10:30 a.m. EST
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and CEO
Webcast: View Source;kiosk=true

Conference: H.C. Wainwright Bioconnect Virtual Conference, January 10-13, 2022
On Demand Presentation Date/Time: Monday, January 10 at 7:00 a.m. EST
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and CEO
Webcast: View Source

To access live and/or archived Investor Conference webcasts, visit the Events & Presentations section of the Company’s website. A replay of Company webcasts is archived on the website for 30 days following presentations.